Related Experiment Video
Updated: Sep 12, 2025
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.8K
REVISITING GLUCAGON ACTION IN DIABETES: IS IT ALL BAD?
1Durham, NC.
Summary
Glucagon, traditionally seen as insulin's opposite, may also stimulate insulin secretion and improve insulin sensitivity. This suggests glucagon receptor agonism could be a novel diabetes treatment.
Area of Science:
- Endocrinology
- Metabolic Diseases
Background:
- Glucagon traditionally counterbalances insulin, preventing hypoglycemia by stimulating hepatic glucose release.
- Elevated glucagon secretion has been implicated in driving hyperglycemia and diabetes development.
Purpose of the Study:
- To investigate the multifaceted roles of glucagon beyond its traditional function.
- To explore the potential of glucagon receptor agonism as a therapeutic strategy for diabetes.
Main Methods:
- Review of clinical studies on insulin-induced hypoglycemia and glucagon response.
- Analysis of in vitro studies on glucagon signaling in hepatocytes.
- Examination of clinical trial data for novel glucagon receptor agonist drugs.
Main Results:
- Glucagon's role extends to stimulating insulin secretion and enhancing hepatic insulin action.
- Distinct actions of glucagon observed in fed versus fasted states.
- Clinical trials show promise for multi-receptor drugs targeting the glucagon pathway.
Conclusions:
- The traditional view of glucagon as solely counter-regulatory to insulin is incomplete.
- Glucagon exhibits complex functions dependent on metabolic state.
- Glucagon receptor agonism presents a potential therapeutic avenue for managing diabetes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
01:16Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
01:15Hypoglycemia and Glucagon
337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
01:02Glucose Homeostasis: Regulation of Blood Glucose
2.5K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.5K
01:06Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263